Press Enter to search · Esc to close
A new gene-metabolite map suggests incretin-pathway drugs act on a web of cardiovascular and metabolic systems — not just glucose. Here's what that means for patients in 2026.
A long-running Japanese cohort and a fresh Indian prevalence study complicate the metabolic-syndrome story — pointing to the components that actually move the mortality needle.
New research is beginning to explain why GLP-1 drugs work brilliantly for some and modestly for others — and what comes after the first generation of blockbusters.
A new meta-analysis pooling seven direct comparisons gives us the cleanest apples-to-apples read yet on how the two big incretin drugs stack up for weight loss.
A new federal survey puts a real number on how many Americans with diabetes are now on GLP-1 shots — and it's reshaping what we should expect from the next wave of metabolic drugs.
A new scoping review reframes obesity as an organelle-level problem — and points to the levers, lifestyle and pharmacological, that actually shift mitochondrial function.
A new narrative review traces how fasting flips the cell's recycling program through AMPK, mTOR and ketone signaling — and how cautiously the human evidence still reads.
Microbiota-targeted therapies, a newly mapped liver enzyme called HYAL1, and Mendelian evidence linking metabolic syndrome to IBD are quietly reshaping how scientists think about type 2 diabetes.
Two new datasets reframe metabolic risk from inevitability to variability — hunting the protective phenotypes that shrug off vascular damage, and the routine labs that flag your five-year diabetes window.
A multicenter analysis suggests that early-pregnancy glucose variability may be a hidden link between higher pre-pregnancy BMI and late-onset hypertensive disorders — and a possible lever for prevention.